The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control

The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Dermatologic therapy Ročník 32; číslo 5; s. e13029 - n/a
Hlavní autori: Grabarek, Beniamin, Krzaczyński, Jakub, Strzałka‐Mrozik, Barbara, Wcisło‐Dziadecka, Dominika, Gola, Joanna
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Hoboken, USA John Wiley & Sons, Inc 01.09.2019
Predmet:
Adult
Dermatologic Agents - pharmacology
Female
Gene Expression Regulation - drug effects
Humans
Interleukin-17 - biosynthesis
Interleukin-17 - genetics
JAK/STAT signaling pathway
Male
Middle Aged
psoriasis
Psoriasis - drug therapy
Psoriasis - genetics
Psoriasis - metabolism
RNA - genetics
Signal Transduction
STAT1 Transcription Factor - biosynthesis
STAT1 Transcription Factor - genetics
STAT3 Transcription Factor - genetics
STAT4 Transcription Factor - biosynthesis
STAT4 Transcription Factor - genetics
Suppressor of Cytokine Signaling Proteins - biosynthesis
Suppressor of Cytokine Signaling Proteins - genetics
ustekinumab
Ustekinumab - pharmacology
Young Adult
psoriasis
JAK/STAT signaling pathway
ustekinumab
ISSN:1396-0296, 1529-8019, 1529-8019
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10 men) The control group consisted of 14 healthy volunteers (7 women, 7 men), their whole blood was used as a material in this study. A quantitative reverse transcription polymerase chain assay was used to amplify analyzed genes. To indicate the differences in expression of selected genes in the test and control groups, the Kruskal–Wallis and the post hoc Dunn's test was carried out. After 40 weeks of observation of the effectiveness of ustekinumab in patients with psoriasis, the expression of STAT1, STAT3, STAT4, IL17, and SOCS2 was silenced. Statistic differences in expression were observed for STAT3 (40 vs. 0 weeks, p < .05; 0 week vs. C, p < .05) and SOCS2 (0 week vs. C, p < .05). Patients with psoriasis vulgaris have higher levels of STAT1, STAT3, STAT4, SOCS2, and IL17 expression compared to healthy individuals. On the other hand, the treatment of ustekinumab lasting 40 weeks caused a decrease in the transcriptional activity of the analyzed genes.
Bibliografia:Funding information
Consent of the Bioethics Commission of Medical University of Silesia, Grant/Award Number: KNW/0022/KB1/59/I/13/14; Medical University of Silesia, Grant/Award Number: KNW‐1‐032/N/9/I
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1396-0296
1529-8019
1529-8019
DOI:10.1111/dth.13029